| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected byan in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ana Isabel Gil-García, Antonio Madejón, Irene Francisco-Recuero, Ana López-López, Emiliana Villafranca, Miriam Romero, Aracel García, Antonio Olveira, Rocío Mena, Juan Ramón Larrubia and Javier García-Samaniego |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Análisis genético y epigenético del VHB en pacientes portadores asintomáticos. Implicaciones en la decisión terapéutica funded in the 1st Edition of the Gilead Fellowship Program |
GLD13/00046 |
| Modificaciones de los niveles de expresión génica mediada por mutantes naturales de la región PreS del virus de la hepatitis B, y asociación con genes implicados en el desarrollo de hepatocarcinoma. Efecto del tratamiento antiviral |
|
|
| Corresponding Author |
Javier García-Samaniego, MD, PhD, Chief Doctor, Hepatology Unit, Hospital Universitario La Paz. Centro de Investigación Biomédica en Red (CIBER). Instituto de Investigación del Hospital Universitario la Paz (IdiPAZ)., Paseo de la Castellana, 261, Madrid 28046, Spain. javiersamaniego@telefonica.net |
| Key Words |
Hepatitis B virus; Hepatocellular carcinoma; PreS deletions; HBV treatment; Grey zone; |
| Core Tip |
The antiviral treatment in patients with chronic hepatitis B in the “grey zone” of treatment is controversial and not clearly indicated. The genetic analysis of hepatitis B virus (HBV) basal core promoter/precore/core and preS regions has shown a high prevalence and persistence of preS deletions in the sub-Saharan population infected with HBV-E/A genotypes. By contrast, Caucasian patients, who have shown a good clinical evolution in previous studies, were negative for these variants. The recognition of these subpopulations warrant to increase the clinical surveillance in order to minimize the risk of liver cancer development due to accumulation of hepatocellular carcinoma-related HBV genetic variants. |
| Publish Date |
2019-10-14 10:47 |
| Citation |
Gil-García AI, Madejón A, Francisco-Recuero I, López-López A, Villafranca E, Romero M, García A, Olveira A, Mena R, Larrubia JR and García-Samaniego J. Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment. World J Gastroenterol 2019; 25(38): 5883-5896 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i38/5883.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i38.5883 |
